Imunoterapia tópica no tratamento do carcinoma basocelular periocular

Macedo, Erick Marcet Santiago de; Carneiro, Rachel Camargo; Matayoshi, Suzana

doi:10.1590/s0034-72802009000600007

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy lasted from 8 to 16 weeks 8 . Patients reported that each cold-stored sachet with 5% imiquimod cream lasted 3 days.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment

Macedo¹,

Carneiro²,

Carricondo³

et al. 2012

Rev. bras.oftalmol.

Self Cite

View full text Add to dashboard Cite

Clinical Trials.gov Identifier: NCT00803907 Apoio do CNPq -processo n° 480144/2008-7 ARTIGO ORIGINAL Recebido para publicação em 2/11/2011 -Aceito para publicação em 2/3/2011 ABSTRACT Purpose: The objective of this study was to compare the estimated cost of clinical and surgical treatment for basl cell carcinoma of the eyelid. Methods: This was a pilot study of 12 patients with basal cell carcinoma receiving treatment with 5% imiquimod cream at the ocular plastic surgery center, medical school University of São Paulo (HC-FMUSP, Brazil). The cost of clinical treatment was estimated based on the time of treatment and amount of medication consumed by patients in the home setting. The cost of surgical treatment was estimated by ophthalmologists with experience in reconstructive plastic surgery based on analysis of images of the same patients. Surgeons responded to a questionnaire with four questions about surgical technique, surgical materials required, estimated duration of surgery and type of anesthesia.Results: Immunotherapy lasted from 8 to 12 weeks. All patients reported each coldstored sachet with 5% imiquimod cream lasted 3 days. According to the institution, a box with 12 sachets costs BRL 480.00. Patients required 1.58-3.11 boxes for complete treatment, corresponding to a total cost of BRL 758.40-1,492.80. Based on image analysis, surgeons evaluated surgery would require 1-3 hours. The estimated cost of surgery room and staff was BRL 263.00, to which the cost of supplies was added. Thus, the total cost of surgical treatment was BRL 272.61-864.82. On the average, immunotherapy was 57,64% more costly than surgical treatment. Conclusions: Malignant eyelid tumors are a common finding in clinical ophthalmology. Surgery is still the treatment of choice at our institution, but immunotherapy with 5% imiquimod cream may be indicated for patients with multiple lesions or high surgical risk and for patients declining surgery for reasons of fear or esthetic concerns. The ability to estimate costs related to the treatment of malignant eyelid tumors is an important aid in the financial planning of health care institutions. Further studies should evaluate the possibility of institutions equating the cost of immunotherapy and surgical treatment by acquiring similar but less expensive medications.

show abstract

“…Immunotherapy lasted from 8 to 16 weeks 8 . Patients reported that each cold-stored sachet with 5% imiquimod cream lasted 3 days.…”

Section: Resultsmentioning

confidence: 99%

“…Exceptions include a study on patients with BCC in the lower limbs 8 and a study comparing dermatological and non-dermatological services. (9) However, no previous study compared the cost of clinical and surgical treatment of BCC in the periocular area.…”

mentioning

confidence: 99%

Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment

Macedo¹,

Carneiro²,

Carricondo³

et al. 2012

Rev. bras.oftalmol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…These markers are molecular target of several marketed drugs. Macedo et al (2009) described a case report about topical immunotherapy for the treatment of periocular basal cell carcinoma and showed that one year after treatment the patient showed no signs of disease recurrence. The Brazilian Journal of Oncology encloses two review articles about several reported tumor markers (Almeida et al, 2007) and tumor markers in breast cancer (Eisenberg and Koifman, 2001) attempting for the importance of clinical diagnostics.…”

Section: Non-specific Therapiesmentioning

confidence: 99%

Immunological Processes in Cancer: A Link Between Inflammation and Immunity

Victorino¹

2014

American Journal of Immunology

View full text Add to dashboard Cite

Cancer is a worldwide issue and one of the most relevant death causes in child and adults. There are several causes that can lead to cancer development. It is well known that inflammation is one known hallmark of cancer and it favors tumor cells growth. Several alterations in immunological and inflammatory processes are caused in response to tumor presence and both innate and adaptive immunity have effective mechanism to destroy tumor cells. Nevertheless, distinct tumor types developed mechanisms to evade anti-tumor immunological responses. Here, we revise researches regarding inflammation and immune response during cancer development, as well as cancer signaling pathways and immunotherapy that have been performed in Brazil. The better understanding of the mechanisms regarding cancer and immunological processes is of huge importance and it may support the development of new cancer targets.

show abstract